camurus®

INTERIM REPORT 2017 **Q1**

CONTENTS

FINANCIAL CALENDAR

Annual General Meeting	3 May 2017
Q2 2017	13 July 2017
Q3 2017	26 October 2017
Full Year Report 2017	15 February 2018
Annual Report 2017	22 March 2018

”New top-line Phase 3 results support the long-term safety and efficacy of CAM2038 in patients with opioid dependence. After completing pre-submission meetings with EMA and FDA, market approval applications for CAM2038 are now being finalized.”

Camurus is committed to developing and commercializing innovative and long-acting medicines for the treatment of severe and chronic conditions, including opioid dependence, pain, cancer and endocrine disorders. New drug products are based on our proprietary FluidCrystal® drug delivery technologies with the purpose to deliver improved quality of life, treatment outcomes and resource utilization. The company’s share is listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit **camurus.com**

Positive study results and continued development towards the market

We had a busy and productive first quarter with five ongoing clinical trials and several studies under initiation. The last patients completed treatment in the Phase 3 long-term safety study of CAM2038, weekly and monthly buprenorphine depots. New top-line Phase 3 results support the long-term safety and efficacy of CAM2038 in patients with opioid dependence. Having concluded pre-submission meetings with EMA and FDA, market approval applications for CAM2038 are now being finalized.

During the first quarter, we completed treatment of all patients in the open-label, long-term safety Phase 3 study of our weekly and monthly depots of buprenorphine together with our US partner Braeburn Pharmaceuticals. 228 patients in Europe, the U.S. and Australia were randomized in the study. Topline results demonstrated that the CAM2038 weekly and monthly depots were well tolerated and provided continuous treatment effect across the 48-week treatment period. Study retention was high, with 71% of patients completing the 48-week study treatment period.

After positive pre-submission meetings with the regulatory authorities (EMA and FDA), we are together with Braeburn Pharmaceuticals finalizing our market marketing authorization application and new drug applications (MAA and NDA) for submissions in mid-2017. The preparations for our anticipated 2018 launch of CAM2038 in Europe is well on-track, with the aim to provide patients rapid access to a new treatment alternative with the potential to improve both treatment outcomes and quality of life.

We are also working to expand the future indications for CAM2038 to treatment of chronic pain and expect to complete the ongoing pivotal Phase 3-study in patients with chronic low-back pain before the end of the year. During the period, a meeting was held with FDA regarding the product registration for chronic pain. There is a significant unmet medical need for new therapeutic options for treating chronic pain, highlighted by the current opioid crisis and issues of diversion, misuse, dependence and overdoses relating to the use of prescription opioids. CAM2038 may effectively address these problems and become an important treatment alternative, including for patients in need for higher doses of opioid analgesics and risks of dependence, and may also provide effective and long-acting pain relief.

In our collaboration with Novartis for our long-acting octreotide depot, CAM2029, for treatment of acromegaly and neuroendocrine tumours, GMP-manufacturing was performed during the period for Novartis' planned start of Phase 3 studies later this year. Results from our previous Phase 2 study of CAM2029 in acromegaly and NET patients were presented at two scientific conferences; ENETS 2017 in Barcelona and ENDO 2017 in Orlando.

In the early clinical pipeline, treatment of the last cohorts is ongoing in the Phase 1 study of CAM2047 for treatment of chemotherapy-induced nausea and vomiting (CINV), and CAM2048 and CAM2058 for treatment of pain, nausea and vomiting. Study results are expected third quarter 2017. We are also preparing the start of the first clinical trial of our subcutaneous treprostinil depot, CAM2043, aiming at the development of a new treatment alternative for pulmonary arterial hypertension (PAH); a rare, serious and life-threatening condition affecting the lungs and heart.

Camurus is expanding with good prospects of further growth and continued value creation. This is reflected by an increasing interest from both pharmaceutical companies and the international investor community, for instance, in connection with our presentations and at J.P. Morgan and Cowen and Co. Annual Health Care Conferences earlier in the year.

In parallel with the advances in our product pipeline, we are also building our commercial organization for the anticipated launch of CAM2038 in 2018. To support the business expansion, we have strengthened the management team and organization with new functions and expertise. Urban Paulsson, with broad and international expertise from the pharmaceutical industry, was recently appointed as VP Corporate Development & General Counsel, and Cecilia Callmer, previously at Novo Nordisk and Ferring Pharmaceuticals, has taken the position as VP Human Resources.

We have had a good start of the year, with the recent announcement of positive Phase 3 results, and are now about to enter the registration phase with CAM2038. We are also having good progress in other clinical programs and look forward to a continued positive news flow during the year.

Fredrik Tiberg
President & CEO

Q1

Business highlights

- All patients completed treatment in Phase 3 long-term safety study of long-acting buprenorphine depots in opioid dependent patients.
- Pre-MAA/NDA meetings held with EMA and FDA for weekly and monthly buprenorphine depots for treatment of opioid use disorder.
- Presentation of Phase 2 results for long-acting octreotide at ENETS 2017 in Barcelona.
- Publication of pharmacokinetic Phase 1 results for weekly and monthly buprenorphine depots in Advances in Therapy.
- Corporate presentations at J.P. Morgan Annual Healthcare Conference 2017 and Cowen and Co. Annual Health Care Conference 2017.
- Distribution agreement signed with Ethypharm for episil® oral liquid in France.
- Urban Paulsson appointed as VP Corporate Development and General Counsel and Cecilia Callmer as VP Human Resources.

Significant events after the reporting period

- Positive topline Phase 3 results from long-term safety study of CAM2038 for opioid dependence.

Financial summary

- Revenues MSEK 17.2 (20.2).
- Operating result MSEK -51.6 (-24.9).
- Result after tax MSEK -40.2 (-19.4).
- Earnings per share SEK -1.08 (-0.52), before and after dilution.
- Cash position MSEK 463.8 (571.9).

A strong and diversified pipeline

Camurus is a research-based pharmaceutical company with a focus on the development and commercialization of new and innovative pharmaceuticals for serious and chronic conditions, where there are clear medical needs and the potential to significantly improve treatment. For the development of new drug candidates Camurus utilizes its own proprietary formulation technology, for example, the long-acting injection depot FluidCrystal®. New proprietary medicines with improved properties and treatment outcomes are developed by combining the company's patented drug delivery technologies with active ingredients with documented safety and efficacy profiles. These are developed with significantly lower cost and risk, compared with the development of completely new pharmaceuticals. Camurus' development pipeline contains product candidates for treatment of cancer and the side effects of cancer treatment, endocrine diseases, pain and addiction, see figure. A summary and status update on the different projects is given below.



1) Chemotherapy induced nausea and vomiting, 2) Postoperative nausea and vomiting. 3) Pulmonary arterial hypertension.

CAM2038 – opioid dependence

Opioid dependence is a serious, chronic, relapsing disease and a growing global health problem. Medication assisted treatment (MAT) with daily buprenorphine and methadone represents current standard of care and has been shown effective in reducing withdrawal and cravings, misuse and spreading of diseases. However, these treatments are also associated with limitations such as poor treatment adherence, misuse, medication diversion, and accidental pediatric exposure. CAM2038 includes two long-acting subcutaneous buprenorphine depots for treatment of opioid dependence. The products are based on Camurus' proprietary FluidCrystal® Injection depot technology and are intended for either weekly (q1w) or monthly (q4w) administration by healthcare personnel using prefilled syringes, provided with multiple doses, to allow individualized treatment of patients with opioid dependence. Patients being treated with CAM2038 are freed from the burden and stigma associated with the daily, often supervised, distribution and administration of present buprenorphine medications. CAM2038 also has the potential to generate substantial savings for healthcare and society by reducing costs of frequent supervised treatment, improving treatment compliance and lowering diversion, misuse and abuse.

STATUS Q1

In November 2016, we announced positive results from a pivotal, randomized, double-blind, double-dummy, active-controlled, 24 weeks, efficacy Phase 3 trial of CAM2038. The results demonstrated that CAM2038 met both primary and secondary endpoints in terms of non-inferior respectively superior efficacy of CAM2038 versus daily sublingual buprenorphine/naloxone which is the current Standard of Care. In the first quarter, we completed treatment of opioid patients in the second Phase 3 trial of CAM2038; an open-label, long-term safety study in patients with opioid use disorder. Positive topline results from this study were reported in May 2, 2017.

Furthermore, a Phase 2 study evaluating pharmacokinetics of CAM2038 during repeated dosing is being completed (see chronic pain section). These studies are part of the registration program, which has been agreed with both FDA and EMA. CAM2038 has previously been granted Fast Track status for the treatment of opioid dependence by the FDA, and applications for marketing approvals in the US and Europe are planned to be submitted in mid-2017.

CAM2038 – chronic pain

Chronic pain is a global health problem, and is causing deterioration in general health, reduced quality of life, decreased work capacity and dependence and misuse of strong opioids. CAM2038 is being developed to provide round-the-clock pain relief, while decreasing the risks of respiratory depression and fatal overdoses associated with full μ-opioid agonists, such as morphine, oxycodone and fentanyl. The properties of CAM2038 are considered to conform to the targeted properties for treatments of chronic pain, i.e. the combination of long lasting efficacious analgesia with a reduced risk of misuse, abuse and illicit diversion.

STATUS Q1

In patients with chronic pain and opioid dependence, the Phase 2 trial of CAM2038 assessing pharmacokinetics, analgesia and safety profiles of repeat doses of weekly and monthly CAM2038 is progressing; two dose groups have been completed and an additional dose group has been included. The study is presently being finalized and results are expected in the second quarter 2017. In parallel, a Phase 3 pivotal trial assessing efficacy of CAM2038 in patients with moderate to severe chronic lower back pain is ongoing.

CAM2029 – acromegaly and NET

CAM2029 is being developed by Novartis, with support from Camurus, for the treatment of acromegaly and neuroendocrine tumors. The product offers important potential advantages over current marketed products, including easy administration, significantly increased bioavailability of octreotide, and potential for enhanced treatment efficacy in patients for whom current treatments provide only suboptimal treatment effects. CAM2029 is a ready-to-use, long-acting subcutaneous injection depot of the active substance octreotide formulated with Camurus' proprietary FluidCrystal® Injection depot technology. It is provided in a prefilled syringe, thus not requiring any preparations or temperature conditioning prior to administration. Due to the superior ease of handling and administration, CAM2029 can be conveniently administered by the patients' themselves.

STATUS Q1

The recently completed Phase 2 trial of CAM2029 demonstrated long-acting octreotide release with well-maintained control of symptoms and disease biomarkers after switching patients from the current market leading product Sandostatin® LAR®. The efficacy evaluation was based on assessment of the control of symptoms in NET patients and plasma levels of insulin growth factor-1 and growth hormone in acromegaly patients. The results were presented in March at European Neuroendocrine Tumor Society 2017 in Barcelona, Spain, and in April at the Endocrine Society Annual Meeting, ENDO 2017, Orlando, Florida. Full publication is being compiled. Furthermore, Novartis, in collaboration with Camurus, is completing GMP manufacturing and other preparations of Phase 3 trials of CAM2029, planned to start in 2017.

CAM2032 – prostate cancer

The well established hormone therapies for prostate cancer based on using gonadotropinreleasing hormone agonists such as leuprolide, are aiming at reduction of the testosterone level and thereby impeding the growth of cancer cells. CAM2032 is a long-acting subcutaneous leuprolide depot for treatment of prostate cancer. Additional potential indications for CAM2032 include precocious puberty, gender identity disorders, and endometriosis. This monthly depot is based on Camurus' FluidCrystal® Injection depot technology and will be provided as a small dose volume in a prefilled syringe requiring no reconstitution or conditioning. CAM2032 is being developed for easy subcutaneous injections by patients themselves.

STATUS Q1
Discussions with potential partners for further clinical development are ongoing.

Early Pipeline Projects

At Camurus, we continuously assess new opportunities where our drug delivery technologies effectively can be used to develop differentiated products. Our new pipeline projects are generated in-house as well as in partnership with international biotech and pharmaceutical companies

STATUS Q1

CAM4071
CAM4071 is a product candidate in clinical development under the option, collaboration and licensing agreement with Novartis. The product is a long-acting formulation of an undisclosed peptide based on the FluidCrystal® Injection depot. A Phase 1 trial of pharmacokinetics and pharmacodynamics, performed together with Novartis, has been completed and is being reported.

CAM2047 CAM2048, and CAM2058
CAM2047, CAM2048, and CAM2058 are three investigational drug products based on Camurus' FluidCrystal® Injection depot and are currently evaluated in a Phase 1 trial. These investigational products are being developed for treatment of chemotherapy induced nausea and vomiting (CAM2047), pain (CAM2048) and combined treatment of postoperative pain, nausea and vomiting (CAM2058). Results from the clinical study are expected during the third quarter 2017.

CAM2043
CAM2043 is a new long-acting subcutaneous treprostinil depot, based on Camurus' FluidCrystal® injection depot, being developed for treatment of pulmonary arterial hypertension (PAH). Data from the recently completed preclinical program show promising plasma exposure with treprostinil, comparable with those reported in infusion studies, and no significant reactions at the injection site. A potential clinical development program is being evaluated for a possible start during the second half-year of 2017.

Medical device – episil®

episil® oral liquid is a medical device for treatment of inflammatory and painful conditions in the oral cavity. The product provides fast pain relief and protection of sore and inflamed mucosal surfaces, caused by e.g. oral mucositis, a common and serious side effect of cancer treatment. In contact with the buccal membrane, episil® transforms into a thin protective layer of gel, offering effective pain relief for up to 8 hours. episil® oral liquid is based on Camurus' FluidCrystal® topical bioadhesive technology.

STATUS Q1
In December, Camurus' partner Solasia Pharma signed an agreement with Meiji Seika Pharma for commercialization of episil® in Japan. Market registration processes are ongoing in Japan and China. During the period, Camurus signed an agreement with Ethypharm for the distribution of episil® in France. In the US, Camurus partner, R-Pharm continues launching of episil®, with initial focus on breast cancer patients.

FINANCIAL OVERVIEW

REVENUES

Revenues during the quarter amounted to MSEK 17.2 (20.2), generated from license agreements, project activities and product sales.

OPERATING RESULT

Marketing, business development and distribution costs during the quarter, were MSEK 7.1 (4.3).

Administrative expenses amounted to MSEK 4.4 (3.7).

R&D costs, including depreciation and amortization of tangible and intangible assets were MSEK 54.1 (35.4).

Other operating expenses mainly consist of currency exchange losses in operational activities, were MSEK 0.1 (1.7).

The operating result for the quarter was MSEK -51.6 (-24.9).

FINANCIAL ITEMS AND TAX

Financial items for the period was MSEK -0.0 (-0.0).

Tax was MSEK 11.3 (5.5) and is mainly attributable to deferred tax for losses during the quarter.

RESULT FOR THE PERIOD

The result for the period was MSEK -40.2 (-19.4), corresponding to earnings per share of SEK -1.08 (-0.52) before and after dilution.

CASH FLOW AND INVESTMENTS

Cash flow from operating activities, before change in working capital, was negative and amounted to MSEK -50.6 (-34.0).

Change in working capital affected the cash flow positively by MSEK 7.0 (-110.1) and the difference relates to the payment in January 2016 of withheld tax and social security costs for the share-based bonus program, which was effectuated in connection with the listing of the Company's shares on Nasdaq Stockholm in December 2015.

Cash flow from investing activities was MSEK -1.2 (-0.1).

CASH

The Company's cash position as of March 31, 2017, was MSEK 463.8 (571.9). The difference compared to previous year is mainly attributable to the operating result.

There were no outstanding loans as of March 31, 2017, and no loans have been taken up since.

EQUITY

Consolidated equity as of March 31, 20167 was MSEK 524.2 (621.1).

ACQUISITIONS

As a part of the establishment of the European commercial organization, a wholly owned subsidiary has been set up in UK.

CAMURUS' SHARE

Camurus' share is listed on Nasdaq Stockholm since the December 3, 2015. At the end of the period, the total number of shares in the company was 37,281,486 (37,281,486).

In accordance with a decision by a Shareholder's General Meeting in May 2016, an incentive program (TO2016 / 2019) under which a maximum of 550 000 warrants can be issued, was introduced. The dilution of a full utilization of the program corresponds to 1.5% of the share capital and voting rights. The number of warrants that have been issued are 550 000 and which give the right to subscribe for an equal number of shares during the period May 15, 2019 - December 15, 2019. During the quarter, no warrants have been subscribed for and as by end of March 31, 2017, 404 300 warrants had been subscribed for in total.

PARENT COMPANY

Revenues for the quarter amounted to MSEK 17.3 (20.0) and the result after tax was MSEK -39.9 (-19.0).

On March 31, 2017, equity in the Parent Company amounted to MSEK 507.1 (603.6).

Total assets at the end of the period was MSEK 584.6 (661.4) of which MSEK 463.6 (571.9) were cash and cash equivalents.

OTHER DISCLOSURES

PERSONNEL

At the end of the period, Camurus had 64 (49) employees, of whom 47 (36) were within research and development. The full time equivalent employees (FTEs) during the quarter was 59 (48).

SIGNIFICANT RISKS AND UNCERTAINTIES

The company management makes estimates and assumptions about the future. Such estimates can deviate considerably from the actual outcome, since they are based on various assumptions and experiences.

The estimates and assumptions that may lead to the risk of significant adjustments to reported amounts for assets and liabilities relate mainly to measurement and allocation of revenues and costs in connection with licensing agreements and deferred tax receivables.

Risks in ongoing development projects comprise technical and manufacturing related risks (including products failing to meet set specifications post manufacturing), safety and effect-related risks that can arise in clinical trials, regulatory risks relating to non-approval or delays of clinical trial applications and market approvals, and commercial risks relating to the sale of proprietary and competing products and their development on the market, as well as IP risks relating to approval of patent applications and patent protection. In addition, there are risks relating to the development, strategy and management decisions of Camurus' partners. Camurus pursues operations and its business on the international market and the Company is therefore exposed to currency risks, since revenues and costs arise in different currencies, mainly SEK, EUR and USD.

The Board of Directors has not changed its outlook on future developments in relation to their outlook published in the annual report for 2016.

ANNUAL GENERAL MEETING 2017

Camurus Annual General Meeting 2017 will be held on Wednesday 3 May, at 17.00 CET, at Elite Hotel Ideon, Scheelevägen 27, Ideon Science Park, 223 63 Lund.

AUDIT

This report has not been reviewed by the company's auditors.

FURTHER INFORMATION

For further information, please contact:
Fredrik Tiberg, Chief Executive Officer
Rein Piir, VP Investor Relations
Tel.: +46 46 286 46 92, e-mail: ir@camurus.com.

Lund, May 3, 2017
Camurus AB
Board of Directors

Financial statements

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

KSEK	Note	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Net sales	3	17,192	20,246	113,737
Cost of goods sold		-32	-63	-2,140
Gross profit		**17,161**	**20,183**	**111,597**
Marketing and distribution costs		-7,093	-4,298	-24,738
Administrative expenses		-7,412	-3,715	-17,985
Research and development costs		-54,143	-35,394	-172,077
Other operating income		–	16	751
Other operating expenses		-101	-1,650	–
Operating result		**-51,588**	**-24,857**	**-102,452**
Finance income		1	2	95
Finance expenses		-3	-37	-1,002
Net financial items		**-2**	**-35**	**-907**
Result before tax		**-51,590**	**-24,893**	**-103,359**
Income tax	8	11,343	5,476	22,367
Result for the period		**-40,247**	**-19,416**	**-80,993**

Total comprehensive income is the same as the result for the period, as the consolidated group contains no items that are recognized under other comprehensive income. Total comprehensive income is attributable to parent company shareholders

EARNINGS PER SHARE, based on earnings attributable to parent company shareholders for the period (in SEK per share)

SEK	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Earnings per share before dilution, SEK	-1,08	-0,52	-2,17
Earnings per share after dilution, SEK	-1,08	-0,52	-2,17

Presently, the company has one subscription warrant program active. For further information see page 8, Camurus' share.

CONSOLIDATED BALANCE SHEET

KSEK	Note	31-03-2017	31-03-2016	31-12-2016
ASSETS				
Fixed assets				
Intangible assets				
Capitalized development expenditure		18,219	20,303	18,741
Tangible assets				
Equipment		10,463	6,450	9,759
Financial assets				
Long-term receivables Group companies		–	–	–
Deferred tax receivables	8	73,027	44,794	61,685
Total fixed assets		**101,710**	**71,546**	**90,185**
Current assets				
Inventories				
Finished goods, raw materials and products in work		8,251	3,157	12,380
Current receivables				
Receivables from Group companies		–	–	–
Trade receivables		6,689	14,170	8,304
Other receivables		5,459	6,015	3,855
Prepayments and accrued income		11,681	9,381	16,459
Total current receivables	5	**23,829**	**29,566**	**28,618**
Cash and cash equivalents		**463,804**	**571,916**	**508,594**
Total current assets		**495,884**	**604,640**	**549,592**
TOTAL ASSETS		**597,593**	**676,186**	**639,776**

KSEK	Note	31-03-2017	31-03-2016	31-12-2016
EQUITY				
Equity attributable to parent company shareholder				
Share capital		932	932	932
Other contributed capital		631,034	626,181	631,034
Retained earnings, including result for the period		-107,797	-5,972	-67,549
Total equity	9	**524,170**	**621,141**	**564,418**
LIABILITIES				
Long-term liabilities				
Deferred tax liability		–	–	–
Total long-term liabilities		**–**	**–**	**–**
Short-term liabilities				
Liabilities to Group companies		–	–	–
Trade payables		13,053	7,566	17,560
Income taxes		–	–	–
Other liabilities		6,225	3,890	2,571
Accrued expenses and deferred income		54,145	43,589	55,228
Total short-term liabilities		**73,424**	**55,045**	**75,358**
TOTAL EQUITY AND LIABILITIES		**597,593**	**676,186**	**639,776**

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

KSEK	Note	Share capital	Other contributed capital	Retained earnings, including result for the period	Total equity
Opening balance 1 January 2016		**932**	**626,181**	**13,444**	**640,557**
Result for the period and comprehensive income				-19,416	-19,416
Transactions with shareholders		**–**	**–**	**–**	**–**
Closing balance 31 Mars 2016		**932**	**626,181**	**-5,972**	**621,141**
Opening balance 1 January 2016		**932**	**626,181**	**13,444**	**640,557**
Result for the period and comprehensive income				-80,993	-80,993
Transactions with shareholders					
Warrants issued			4,853		4,853
Closing balance 31 December 2016		**932**	**631,034**	**-67,549**	**564,418**
Opening balance 1 January 2017		**932**	**631,034**	**-67,549**	**564,418**
Result for the period and comprehensive income				-40,248	-40,248
Transactions with shareholders					
Warrants issued		–	–	–	–
Closing balance 31 March 2017	9	**932**	**631,034**	**-107,797**	**524,170**

CONSOLIDATED STATEMENT OF CASH FLOW

KSEK	Note	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Operating activities				
Operating profit/loss before financial items		-51,588	-24,857	-102,452
Adjustments for non-cash items	7	1,013	840	3,524
Interest received		1	2	95
Interest paid		-3	-37	-1,002
Income taxes paid		–	-9,917	-9,917
		-50,577	**-33,969**	**-109,752**
Increase/decrease in inventories		4,129	84	-9,139
Increase/decrease in trade receivables		1,616	-5,253	613
Increase/decrease in other current receivables		3,174	5,923	1,005
Increase/decrease in trade payables		-4,507	-24,266	-14,272
Increase/decrease in other current operating liabilities		2,569	-86,564	-76,243
Cash flow from changes in working capital		***6,981***	***-110,076***	***-98,036***
Cash flow from operating activities		**-43,596**	**-144,045**	**-207,788**
Investing activities				
Acquisition of intangible assets		–	–	–
Acquisition of tangible assets		-1,195	-135	-4,567
Divestment/amortization of other financial assets		–	–	–
Increase/decrease in current financial investments		–	–	–
Cash flow from investing activities		**-1,195**	**-135**	**-4,567**
Financing activities				
Increase/decrease in current financial liabilities		–	–	–
Warrants issued		–	–	4,853
Cash flow from financing activities		**–**	**–**	**4,853**
Net cash flow for the period		**-44,791**	**-144,180**	**-207,502**
Cash and cash equivalents at beginning of period		508,594	716,096	716,096
Exchange rate differences in cash equivalents		–	–	–
Cash and cash equivalents at the end of period		**463,804**	**571,916**	**508,594**

INCOME STATEMENT – PARENT COMPANY

KSEK	Note	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Net sales		17,337	20,246	113,737
Cost of goods sold		-32	-63	-2,140
Gross profit		**17,305**	**20,183**	**111,597**
Marketing and distribution costs		-7,232	-4,298	-24,738
Administrative expenses		-7,555	-3,715	-17,985
Research and development costs		-53,621	-34,873	-169,994
Other operating income		–	16	751
Other operating expenses		-101	-1,650	–
Operating result before items affecting comparability		**-51,204**	**-24,337**	**-100,370**
Result from interests in Group companies		–	–	–
Interest income and similar items		1	2	95
Interest expense and similar items		-3	-37	-1,002
Result after financial items		**-51,206**	**-24,372**	**-101,277**
Appropriations		–	–	-1,246
Result before tax		**-51,206**	**-24,372**	**-102,523**
Tax on profit for the period	8	11,265	5,362	22,183
Result for the period		**-39,941**	**-19,010**	**-80,340**

Total comprehensive income is the same as profit/loss for the period, as the parent company contains no items that are recognized under other comprehensive income.

BALANCE SHEET – PARENT COMPANY

KSEK	Note	31-03-2017	31-03-2016	31-12-2016
ASSETS				
Fixed assets				
Tangible fixed assets				
Equipment		10,463	6,450	9,759
Financial fixed assets				
Interest in Group companies		816	573	816
Deferred tax assets	8	77,839	49,753	66,574
Total fixed assets		**89,118**	**56,775**	**77,149**
Current assets				
Inventories				
Finished goods, raw materials and products in work		8,251	3,157	12,380
Current receivables				
Receivables from parent company		–	–	–
Trade receivables		6,689	14,170	8,304
Other receivables		5,244	6,015	3,855
Prepayments and accrued income		11,681	9,383	16,459
Total current receivables		**23,614**	**29,568**	**28,618**
Cash and bank deposits		**463,566**	**571,916**	**508,351**
Total current assets		**495,431**	**604,642**	**549,351**
TOTAL ASSETS		**584,549**	**661,417**	**626,499**

KSEK	Note	31-03-2017	31-03-2016	31-12-2016
EQUITY AND LIABILITIES				
Restricted equity				
Restricted equity (37 281 486 shares)		932	932	932
Statutory reserve		11,327	11,327	11,327
Total restricted equity		**12,259**	**12,259**	**12,259**
Unrestricted equity				
Retained earnings		-62,595	17,746	17,746
Share premium reserve		597,418	592,565	597,418
Result for the period		-39,941	-19,010	-80,340
Total unrestricted equity		**494,883**	**591,300**	**534,823**
TOTAL EQUITY		**507,142**	**603,560**	**547,083**
LIABILITIES				
Untaxed reservesr				
Depreciation/amortization in excess of plan		3,486	2,239	3,486
Total untaxed reserves		**3,486**	**2,239**	**3,486**
Long-term liabilities				
Liability to subsidiaries		1,945	573	573
Total long-term liabilities		**1,945**	**573**	**573**
Short-term liabilities				
Liabilities to Group companies		–	–	–
Trade payables		13,053	7,566	17,560
Current tax liability		–	–	–
Other liabilities		5,130	3,890	2,571
Accrued expenses and deferred income		53,793	43,589	55,227
Total short-term liabilities		**71,976**	**55,045**	**75,358**
TOTAL EQUITY AND LIABILITIES		**584,549**	**661,417**	**626,499**

KEY FIGURES AND DEFINITIONS

Key figures, MSEK	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Net revenues	17,2	20,2	113,7
Operating result	-51,6	-24,9	-102,5
Result for the period	-40,2	-19,4	-81,0
Cash flow from operating activities	-43,6	-144,0	-207,8
Cash and cash equivalents	463,8	571,9	508,6
Equity	524,2	621,1	564,4
Equity ratio in Group, percent	88%	92%	88%
Total assets	597,6	676,2	639,8
Average number of shares, before dilution	37 281 486	37 281 486	26 281 486
Average number of shares, after dilution*)	37 685 786	37 281 486	37 487 937
Earnings per share before dilution, SEK	-1,08	-0,52	-2,17
Earnings per share after dilution, SEK*)	-1,08	-0,52	-2,17
Equity per share before dilution, SEK	14,06	16,66	15,14
Equity per share after dilution, SEK*)	13,91	16,66	15,06
Number of employees at end of period	64	49	62
Number of employees in R&D at end of period	47	36	44
R&D costs as a percentage of operating expenses	79%	82%	80%

**) The dilution effect is calculated according to IAS 33*

Cash and cash equivalents
Cash and cash bank balances

Equity ratio, % Equity divided by total capital

Average number of shares, before dilution
Weighted average number of shares before adjustment for dilution effect of net shares

Average number of shares, after dilution
Weighted average number of shares adjustment for the dilution effect of new shares

Earnings per share before dilution, SEK
Result divided by the weighted average number of shares outstanding before dilution

Earnings per share after dilution, SEK
Result divided by the weighted average number of shares outstanding after dilution

Equity per share before dilution, SEK
Equity divided by the weighted number of shares at the period before dilution

Equity per share after dilution, SEK
Equity divided by the weighted number of shares at the end of the period after dilution

R&D costs as a percentage of operating expenses
Research and development costs divided by operating expenses, excluding items affecting comparability (marketing and distribution costs, administrative expenses and research and development costs)

Note 1 | General information

Camurus AB, Corp. ID no. 556667-9105 is the parent company of the Camurus Group. Camurus AB's registered offices is based in Lund, Sweden, at Ideon Science Park, 223 70 Lund. Camurus AB Group's interim report for the first quarter 2017 was approved for publication in accordance with a decision from the Board on May 3, 2017.

All amounts are stated in SEK thousand (KSEK), unless otherwise indicated. Figures in brackets refer to the year-earlier period.

Note 2 | Summary of key accounting policies

The consolidated financial statements for the Camurus AB Group ('Camurus') have been prepared in accordance with International Financial Reporting Standards (IFRS) as adopted by the EU, as well as the Swedish Financial Reporting Board's Recommendation RFR 1 Supplementary Accounting Rules for Groups, and the Swedish Annual Accounts Act.

This interim report has been drawn up in accordance with IAS 34, Interim Financial Reporting, the Swedish Annual Accounts Act and RFR 1 Supplementary Accounting Rules for Groups.

The parent company statements have been prepared in accordance with the Annual Accounts Act and recommendation RFR 2 Accounting for legal entities from the Swedish Financial Reporting Board. The application of RFR 2 means that the parent company in the interim report for the legal entity shall apply all EU-approved IFRS standards and statements as far as possible within the framework of the Annual Accounts Act, the Pension Obligations Vesting Act (Tryggandelagen) and taking into consideration the relationship between accounting and taxation. The parent company's accounting policies are the same as for the Group, unless otherwise stated in Note 2.2.

The most important accounting policies that are applied in the preparation of these consolidated financial statements are detailed below.

2.1 BASIS OF PREPARATION OF REPORTS

2.1.1 Changes to accounting policies and disclosures

New or revised IFRS standards that have come into force have not had any material impact on the Group.

2.2 PARENT COMPANY'S ACCOUNTING POLICIES

The parent company applies accounting policies that differ from
those of the Group in the cases stated below.

Internally generated intangible assets

All expenses that relate to the development of internally generated intangible assets are recognized as expenses as they arise.

Interests in subsidiaries

Interests in subsidiaries are reported at cost, less any impairment losses. The cost includes acquisition-related expenses and any additional considerations.

When there is an indication that interests in subsidiaries have decreased in value, a calculation is made of the recoverable amount. If this amount is lower than the reported amount, an impairment is carried out. Impairment losses are recognized under the item "Result from interests in Group companies".

Group contributions

Group contributions paid by the parent company to subsidiaries and Group contributions received from subsidiaries by the parent company are recognized as appropriations.

Financial instruments

IAS 39 is not applied in the parent company and financial instruments are measured at cost.

Share-based payment

Warrant program TO2016/2019

Presently Camurus has one long-term incentive program active. In accordance with a decision by the Annual General Meeting in May 2016, an incentive program, TO2016 / 2019, for the company's employees, under which a maximum of 550,000 warrants can be issued, was introduced. The warrants were valued by an independent institute in accordance with the Black&Scholes model and were acquired by the participants at market value. As part of the program, the participants receive a threepiece stay-on bonus in the form of gross salary addition from the company, equivalent to the amount paid by the participant for its subscription warrants. As the stay-on bonus is conditional on continued employment costs, including social security cost, are expensed over the vesting period and a liability is calculated at each balance sheet date based on how much has been earned. Expenses are recognized as personnel expense in the income statements. -based payment

Note 3 | Segment information

The highest executive decision maker is the function responsible for allocating resources and assessing the operating segments results. In the Group this function is identified as the CEO based on the information he handles. As the business, i.e. the development of pharmaceutical products based on Camurus' technology platform, the Group is organized as an integrated unit, with similar risks and opportunities for the products and services produced, the entire Group's business constitutes one operating segment. The operating segment are monitored in a manner consistent with the internal reporting provided to the chief operating decision maker. In the internal reporting to the CEO, only one segment is used. results.

Group-wide information
To follow is a breakdown of revenues from all products and services.

KSEK	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Sales of development related goods and services	13,927	15,971	68,112
Milestone payments	2,205	–	34,217
Licensing revenues	835	4,275	8,485
Other	225	–	2,923
Total	**17,192**	**20,246**	**113,737**

Revenues from external customers is allocated by country, based on where the customers are located.

KSEK	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Europé	1,375	7,549	22,921
(of which Sweden)	(59)	(1,673)	(3,727)
North America	15,670	12,572	87,359
Other geographical areas	147	125	3,457
Total	**17,192**	**20,246**	**113,737**

Revenue during the quarter of approximately MSEK 13.2 (7.9) relates to one single external customer. All fixed assets are located in Sweden.

Note 4 | Earnings per share

a) Before dilution

Earnings per share before dilution is calculated by dividing the result attributable to shareholders of the parent company by a weighted average number of ordinary shares outstanding during the period. During the period, no shares held as treasury shares by the parent company have been repurchased.

KSEK	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Result attributable to parent company shareholders	-40,247	-19,416	-80,993
Total	**-40,247**	**-19,416**	**-80,993**
Weighted average number of ordinary shares outstanding (thousands)	**37,281**	**37,281**	**37,281**

b) After dilution

In order to calculate earnings per share, the number of existing ordinary shares is adjusted for the dilutive effect of the weighted average number of outstanding ordinary shares. The parent company has one category of ordinary shares with anticipated dilution effect in the form of warrants. For warrants, a calculation is made of the number of shares that could have been purchased at fair value (calculated as the average market price for the year for the parent company's shares), at an amount corresponding to the monetary value of the subscription rights linked to outstanding warrants. The number of shares calculated as above is compared to the number of shares that would have been issued assuming the warrants are exercised.

KSEK	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Result attributable to parent company shareholders	-40,247	-19,416	-80,993
Total	**-40,247**	**-19,416**	**-80,993**
Weighted average number of ordinary shares outstanding (thousands)	**37,281**	**37,281**	**37,281**
Adjustments:			
– warrants (thousands)	404	–	207
– share issues (thousands)	–	–	–
Weighted average number of ordinary shares in calculation of earnings per share after dilution (thousands)	**37,688**	**37,281**	**37,488**

Note 5 | Financial instruments – Fair value of financial assets and liability measured at amortized cost

All of the Group's financial instruments that are measured at amortized cost are short-term and expire within one year. The fair value of these instruments is deemed to correspond to their reported amounts, since discounting effects are minimal.

Carrying amount, KSEK	31-03-2017	31-03-2016	31-12-2016
Loans and receivables			
Trade receivables	6,689	14,170	8,304
Receivables from Group companies	–	–	–
Other receivables	–	–	–
Cash and cash equivalents	463,804	571,916	508,594
Total	**470,493**	**586,086**	**516,898**
Other liabilities			
Other financial liabilities	–	–	–
Liabilities to Group companies	–	–	–
Trade payables	13,053	7,566	17,560
Other current liabilities	191	191	191
Total	**13,244**	**7,757**	**17,751**

Note 6 | Related party transactions

Investor relations services have been acquired from Piir & Partners AB, whose representative is a member of the management team. Pricing is done in accordance with allocation of costs in relation to utilization rate and on market terms. At the end of the period the company had a debt to Piir & Partner AB regarding these services that amounted to MSEK 0.3 (0.2).

Note 7 | Other non-cash items

Adjustment for non-cash items:

KSEK	2017 Jan – March	2016 Jan – March	2016 Jan – Dec
Depreciation	1,013	840	3,524
Total	**1,013**	**840**	**3,524**

Note 8 | Deferred tax

Tax for the quarter amounted to MSEK 11.3 (5.5), primarily attributable to the negative result.

Note 9 | Equity

The change in equity for the quarter is mainly attributable to the loss.

This information is information that Camurus AB is obliged to make public pursuant to the EU Market Abuse Regulation and the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the chief executive officer, 13.00 PM CET on May 3, 2017.

camurus®

Camurus AB | Ideon Science Park, SE-223 70 Lund, Sweden
P +46 46 286 57 30 | F +46 46 286 57 39 | info@camurus.com | **camurus.com**